|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM122665236 |
| 003 |
DE-627 |
| 005 |
20231222195659.0 |
| 007 |
tu |
| 008 |
231222s2002 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0409.xml
|
| 035 |
|
|
|a (DE-627)NLM122665236
|
| 035 |
|
|
|a (NLM)12482395
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Nance, Christina L
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a SDF-1alpha regulates HIV-1-gp120-induced changes in CD79b surface expression and Ig production in activated human B cells
|
| 264 |
|
1 |
|c 2002
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 15.01.2003
|
| 500 |
|
|
|a Date Revised 06.11.2019
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Binding of HIV-1 glycoprotein (gp120) to activated B cells of HIV-infected and HIV-uninfected subjects induces increased cell proliferation, cAMP generation, immunoglobulin (Ig) production and downregulation of the invariant chain, CD79b, of the B-cell receptor. We present evidence that the stromal cell-derived factor-1alpha (SDF-1alpha), itself a B-cell stimulant, reversed gp120-driven downregulation of CD79b in CD40- and IL-4-activated purified HIV-1 seronegative human peripheral blood B cells. SDF-1alpha augmented gp120-induced Ig production, downregulated CXCR4 receptor expression, and alone, exerted no effect on CD79b surface expression, reversed the gp120-induced downregulation of CD79b. These SDF-1alpha-modulated B-cell responses were specifically abrogated by an anti-SDF-1alpha antibody. These data suggest that SDF-1alpha plays an important regulatory role in the altered B-cell responses seen in HIV-1 infection. Further, these findings may enhance the understanding of the pathophysiology of HIV-1 infection and suggest a strategy utilizing SDF-1alpha or related molecules as an anti-HIV therapy
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Research Support, U.S. Gov't, P.H.S.
|
| 650 |
|
4 |
|a Non-programmatic
|
| 650 |
|
7 |
|a Anti-HIV Agents
|2 NLM
|
| 650 |
|
7 |
|a Antigens, CD
|2 NLM
|
| 650 |
|
7 |
|a CD79 Antigens
|2 NLM
|
| 650 |
|
7 |
|a CD79B protein, human
|2 NLM
|
| 650 |
|
7 |
|a CXCL12 protein, human
|2 NLM
|
| 650 |
|
7 |
|a Chemokine CXCL12
|2 NLM
|
| 650 |
|
7 |
|a Chemokines, CXC
|2 NLM
|
| 650 |
|
7 |
|a HIV Envelope Protein gp120
|2 NLM
|
| 650 |
|
7 |
|a Immunoglobulins
|2 NLM
|
| 650 |
|
7 |
|a Receptors, CXCR4
|2 NLM
|
| 700 |
1 |
|
|a Shearer, William T
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 105(2002), 2 vom: 01. Nov., Seite 208-14
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:105
|g year:2002
|g number:2
|g day:01
|g month:11
|g pages:208-14
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 105
|j 2002
|e 2
|b 01
|c 11
|h 208-14
|